Patents Assigned to Teva Biopharmaceuticals USA, Inc.
  • Humanized antibodies against TL1A
    Patent number: 9416185
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: August 16, 2016
    Assignee: TEVA BIOPHARMACEUTICALS USA, INC.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • HUMANIZED ANTIBODIES AGAINST TL1A
    Publication number: 20140315250
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 23, 2014
    Applicant: TEVA Biopharmaceuticals USA, Inc.
    Inventors: Rodger SMITH, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • Humanized antibodies against TL1A
    Patent number: 8728482
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: May 20, 2014
    Assignee: TEVA Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • HUMANIZED ANTIBODIES AGAINST LIGHT AND USES THEREOF
    Publication number: 20130323240
    Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).
    Type: Application
    Filed: August 8, 2013
    Publication date: December 5, 2013
    Applicant: TEVA Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
  • HUMANIZED ANTIBODIES AGAINST CXCR3
    Publication number: 20130274447
    Abstract: Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function.
    Type: Application
    Filed: April 5, 2013
    Publication date: October 17, 2013
    Applicant: Teva Biopharmaceuticals USA, Inc.
    Inventor: Teva Biopharmaceuticals USA, Inc.
  • Humanized antibodies against LIGHT and uses thereof
    Patent number: 8524869
    Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: September 3, 2013
    Assignee: Teva Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
  • Humanized antibodies against CXCR3
    Patent number: 8435522
    Abstract: Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: May 7, 2013
    Assignee: Teva Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke
  • Humanized antibodies against TL1A
    Patent number: 8263743
    Abstract: Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: September 11, 2012
    Assignee: Teva Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey